Back to search
FDAFDA · Food and drugs·Recall number Z-1374-2024

Obsidio Conformable Embolic, Material Numbers (UPN): a) M0013972001010, b) M0013972101010

Published April 3, 2024 · Recall initiated: February 20, 2024

Summary

FDA records medical device Class I recall Z-1374-2024, published April 3, 2024 and initiated February 20, 2024. Recalling firm: Boston Scientific Corporation; Status: Ongoing; Reported quantity: 985 units; Lot: a) M0013972001010, UDI/DI 00191506039332, ALL LOT CODES b) M0013972101010, UDI/DI 00191506043124, ALL LOT CODES. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

An investigation determined that delivery of the Obsidio embolic using the aliquot technique for lower gastrointestinal bleeding embolization poses a high risk of bowel ischemia. The most serious and the most common adverse health consequence, reasonably foreseeable to occur, is the need to perform major surgery such as bowel resection and/or diverting colostomy. Therefore, Boston Scientific does not recommend that the aliquot technique be used to deliver the Obsidio device for lower GI bleed embolization procedures.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Boston Scientific Corporation
Distributor
US
Lot
a) M0013972001010, UDI/DI 00191506039332, ALL LOT CODES b) M0013972101010, UDI/DI 00191506043124, ALL LOT CODES
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Obsidio Conformable Embolic, Material Numbers (UPN): a) M0013972001010, b) M0013972101010 recalled?

Yes. FDA published recall Z-1374-2024 on April 3, 2024. Reported hazard: An investigation determined that delivery of the Obsidio embolic using the aliquot technique for lower gastrointestinal bleeding embolization poses a high risk of bowel ischemia. The most serious and the most common adverse health consequence, reasonably foreseeable to occur, is the need to perform major surgery such as bowel resection and/or diverting colostomy. Therefore, Boston Scientific does not recommend that the aliquot technique be used to deliver the Obsidio device for lower GI bleed embolization procedures.

What should I do if I have this product?

Voluntary: Firm initiated · Letter